Please Wait
Applying Filters...
1. Budesonide, (r)-isomer
2. Budesonide, (s)-isomer
3. Horacort
4. Pulmicort
5. Rhinocort
6. Tarpeyo
1. Pulmicort
2. Entocort
3. Rhinocort
4. 51333-22-3
5. Preferid
6. Rhinocort Aqua
7. Entocort Ec
8. Uceris
9. Pulmicort Respules
10. Respules
11. Budeson
12. Pulmicort Flexhaler
13. Cortivent
14. Micronyl
15. Spirocort
16. Bidien
17. S-1320
18. Map-0010
19. Chebi:3207
20. Q3oks62q6x
21. 51372-29-3
22. Mls000028507
23. Budesonide Mmx
24. Budesonidum
25. Rhinocort Alpha
26. Map0010
27. R01ad05
28. (11beta,16alpha)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
29. 16a(r),17-(butylidenebis(oxy))-11b,21-dihydroxypregna-1,4-diene-3,20-dione
30. Nsc-757788
31. Budenofalk
32. Budesonido
33. Smr000058337
34. Budecort Inhaler
35. Budesonidum [inn-latin]
36. Budesonido [inn-spanish]
37. (r)-budesonide
38. Inflammide
39. Budiair
40. Miflonide
41. Pulmaxan
42. Fvolir
43. 16,17-butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
44. Budesonide [usan:inn:ban:jan]
45. Rhinocort Allergy
46. Pulmaxan Turbohaler
47. Pulmicort (tn)
48. Pulmicort Topinasal
49. Rhinocort (tn)
50. Pulmicort Turbuhaler
51. Budesonide Easyhaler
52. S 1320
53. Ccris 5230
54. Entocort Ec (tn)
55. Sr-01000000101
56. Einecs 257-139-7
57. Mfcd00083259
58. Unii-q3oks62q6x
59. Jorveza
60. Eltair
61. Ultesa
62. Noex
63. Giona Easyhaler
64. 16?,17-[(1rs)-butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione
65. Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11.beta.,16.alpha.)-
66. Prestwick_840
67. Uceris (tn)
68. Ortikos
69. (11-beta,16-alpha)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
70. 16-alpha,17-alpha-butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
71. (rs)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Butyraldehyde
72. Budesonide, >=99%
73. Budesonide [mi]
74. Budesonide [inn]
75. Budesonide [jan]
76. Opera_id_1696
77. Prestwick0_000518
78. Prestwick1_000518
79. Prestwick2_000518
80. Prestwick3_000518
81. Budesonide [usan]
82. Budesonide [vandf]
83. Epitope Id:161750
84. B 7777
85. Schembl4096
86. (+)-16alpha,17alpha-butylidenedioxy-11beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
87. Budesonide [usp-rs]
88. Budesonide [who-dd]
89. Chembl1370
90. Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-
91. Lopac0_000174
92. Bspbio_000475
93. Budesonide (jan/usp/inn)
94. Mls001077323
95. Mls002207112
96. Spbio_002396
97. Bpbio1_000523
98. Gtpl7434
99. Budesonide [orange Book]
100. Dtxsid8020202
101. Hsdb 8279
102. Budesonide [ep Monograph]
103. Uceris Component Budesonide
104. Budesonide [usp Monograph]
105. Hms1569h17
106. Hms2096h17
107. Hms2232d17
108. Hms3259h07
109. Hms3260d09
110. Hms3413b08
111. Hms3413p17
112. Hms3677b08
113. Hms3677p17
114. Hms3713h17
115. Breztri Component Budesonide
116. (rs)-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Butyraldehyde
117. 5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
118. Act03247
119. Bcp05589
120. Eohilia (budesonide Oral Suspension)
121. Tox21_500174
122. Bdbm50354850
123. Symbicort Component Budesonide
124. Budesonide Component Of Uceris
125. Akos015969655
126. Budesonide Component Of Breztri
127. Ac-4697
128. Ccg-204269
129. Cs-2063
130. Db01222
131. Ks-1162
132. Lp00174
133. Nc00626
134. Nsc 757788
135. Sdccgsbi-0050162.p002
136. 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
137. Budesonide Component Of Symbicort
138. Ncgc00021318-05
139. Ncgc00021318-06
140. Ncgc00021318-08
141. Ncgc00021318-18
142. Ncgc00089747-04
143. Ncgc00260859-01
144. Bb164267
145. Budesonide 100 Microg/ml In Acetonitrile
146. Cpd000058337
147. Hy-13580
148. Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-beta,16-alpha)-
149. Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(r))-, And 16alpha,17-((s)-butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
150. B3909
151. Budesonide 100 Microg/ml In Methanol/water
152. Eu-0100174
153. D00246
154. T70986
155. 333b223
156. Q422212
157. J-504150
158. Q-101375
159. Sr-01000000101-2
160. Sr-01000000101-6
161. Brd-a34299591-001-03-4
162. Budesonide, European Pharmacopoeia (ep) Reference Standard
163. Budesonide, United States Pharmacopeia (usp) Reference Standard
164. Budesonide, Pharmaceutical Secondary Standard; Certified Reference Material
165. (11?,16?)-16,17-[butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
166. (1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
167. (4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
168. (6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
| Molecular Weight | 430.5 g/mol |
|---|---|
| Molecular Formula | C25H34O6 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 430.23553880 g/mol |
| Monoisotopic Mass | 430.23553880 g/mol |
| Topological Polar Surface Area | 93.1 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 862 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 14 | |
|---|---|
| Drug Name | Budesonide |
| Drug Label | Budesonide, the active ingredient of ENTOCORT EC capsules, is a synthetic corticosteroid. It is designated chemically as (RS)-11, 16, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided a... |
| Active Ingredient | Budesonide |
| Dosage Form | Spray, metered; Capsule; Solution; Suspension |
| Route | Nasal; Inhalation; Topical foam; Oral |
| Strength | 0.032mg/inh; 1mg/2ml; 0.5mg/2ml; 2mg; 3mg; 0.25mg/2ml |
| Market Status | Tentative Approval; Prescription |
| Company | Watson Labs; Barr Labs Div Teva; Teva Pharms; Apotex; Salix Pharms; Sandoz; Mylan |
| 2 of 14 | |
|---|---|
| Drug Name | Entocort ec |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | Budesonide, the active ingredient of ENTOCORT EC capsules, is a synthetic corticosteroid. It is designated chemically as (RS)-11, 16, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided a... |
| Active Ingredient | Budesonide |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 3mg |
| Market Status | Prescription |
| Company | Astrazeneca |
| 3 of 14 | |
|---|---|
| Drug Name | Pulmicort flexhaler |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | Budesonide, the active component of PULMICORT FLEXHALER, is a corticosteroid designated chemically as (RS)-11, 16, 17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two ep... |
| Active Ingredient | Budesonide |
| Dosage Form | Powder, metered |
| Route | Inhalation |
| Strength | 0.16mg/inh; 0.08mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 4 of 14 | |
|---|---|
| Drug Name | Pulmicort respules |
| Drug Label | Budesonide, the active component of PULMICORT RESPULES, is a corticosteroid designated chemically as (RS)-11, 16, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with butyraldehyde. Budesonide is provided as a mixture of t... |
| Active Ingredient | Budesonide |
| Dosage Form | Suspension |
| Route | Inhalation |
| Strength | 0.5mg/2ml; 0.25mg/2ml; 1mg/2ml |
| Market Status | Prescription |
| Company | Astrazeneca |
| 5 of 14 | |
|---|---|
| Drug Name | Rhinocort |
| PubMed Health | Budesonide/Formoterol (By breathing) |
| Drug Classes | Antiasthma, Anti-Inflammatory/Bronchodilator Combination, Respiratory Agent |
| Drug Label | Budesonide, the active ingredient of RHINOCORT AQUA Nasal Spray, is an anti-inflammatory synthetic corticosteroid.It is designated chemically as (RS)-11-beta, 16-alpha, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with butyrald... |
| Active Ingredient | Budesonide |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | 0.032mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 6 of 14 | |
|---|---|
| Drug Name | Symbicort |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Active Ingredient | formoterol fumarate dihydrate; Budesonide |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.16mg/inh; 0.08mg/inh; 0.0045mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 7 of 14 | |
|---|---|
| Drug Name | Uceris |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | UCERIS (budesonide) extended release tablets, for oral administration, contain budesonide, a synthetic corticosteroid, as the active ingredient. Budesonide is designated chemically as (RS)-11, 16, 17,21 tetrahydroxypregna-1,4-diene-3,20-dione cyc... |
| Active Ingredient | Budesonide |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 9mg |
| Market Status | Prescription |
| Company | Santarus |
| 8 of 14 | |
|---|---|
| Drug Name | Budesonide |
| Drug Label | Budesonide, the active ingredient of ENTOCORT EC capsules, is a synthetic corticosteroid. It is designated chemically as (RS)-11, 16, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided a... |
| Active Ingredient | Budesonide |
| Dosage Form | Spray, metered; Capsule; Solution; Suspension |
| Route | Nasal; Inhalation; Topical foam; Oral |
| Strength | 0.032mg/inh; 1mg/2ml; 0.5mg/2ml; 2mg; 3mg; 0.25mg/2ml |
| Market Status | Tentative Approval; Prescription |
| Company | Watson Labs; Barr Labs Div Teva; Teva Pharms; Apotex; Salix Pharms; Sandoz; Mylan |
| 9 of 14 | |
|---|---|
| Drug Name | Entocort ec |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | Budesonide, the active ingredient of ENTOCORT EC capsules, is a synthetic corticosteroid. It is designated chemically as (RS)-11, 16, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided a... |
| Active Ingredient | Budesonide |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 3mg |
| Market Status | Prescription |
| Company | Astrazeneca |
| 10 of 14 | |
|---|---|
| Drug Name | Pulmicort flexhaler |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | Budesonide, the active component of PULMICORT FLEXHALER, is a corticosteroid designated chemically as (RS)-11, 16, 17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two ep... |
| Active Ingredient | Budesonide |
| Dosage Form | Powder, metered |
| Route | Inhalation |
| Strength | 0.16mg/inh; 0.08mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 11 of 14 | |
|---|---|
| Drug Name | Pulmicort respules |
| Drug Label | Budesonide, the active component of PULMICORT RESPULES, is a corticosteroid designated chemically as (RS)-11, 16, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with butyraldehyde. Budesonide is provided as a mixture of t... |
| Active Ingredient | Budesonide |
| Dosage Form | Suspension |
| Route | Inhalation |
| Strength | 0.5mg/2ml; 0.25mg/2ml; 1mg/2ml |
| Market Status | Prescription |
| Company | Astrazeneca |
| 12 of 14 | |
|---|---|
| Drug Name | Rhinocort |
| PubMed Health | Budesonide/Formoterol (By breathing) |
| Drug Classes | Antiasthma, Anti-Inflammatory/Bronchodilator Combination, Respiratory Agent |
| Drug Label | Budesonide, the active ingredient of RHINOCORT AQUA Nasal Spray, is an anti-inflammatory synthetic corticosteroid.It is designated chemically as (RS)-11-beta, 16-alpha, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with butyrald... |
| Active Ingredient | Budesonide |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | 0.032mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 13 of 14 | |
|---|---|
| Drug Name | Symbicort |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Active Ingredient | formoterol fumarate dihydrate; Budesonide |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.16mg/inh; 0.08mg/inh; 0.0045mg/inh |
| Market Status | Prescription |
| Company | Astrazeneca |
| 14 of 14 | |
|---|---|
| Drug Name | Uceris |
| PubMed Health | Budesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent, Gastrointestinal Agent |
| Drug Label | UCERIS (budesonide) extended release tablets, for oral administration, contain budesonide, a synthetic corticosteroid, as the active ingredient. Budesonide is designated chemically as (RS)-11, 16, 17,21 tetrahydroxypregna-1,4-diene-3,20-dione cyc... |
| Active Ingredient | Budesonide |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 9mg |
| Market Status | Prescription |
| Company | Santarus |
Anti-Inflammatory Agents; Bronchodilator Agents; Glucocorticoids
National Library of Medicine's Medical Subject Headings. Budesonide. Online file (MeSH, 2015). Available from, as of November 20, 2015: https://www.nlm.nih.gov/mesh/MBrowser.html
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Budesonide is included in the database.
NIH/NLM; ClinicalTrials.Gov. Available from, as of September 30, 2015: https://clinicaltrials.gov/search/intervention=budesonide
Budesonide capsules (enteric coated) are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. /Included in US product label/
NIH; DailyMed. Current Medication Information for Budesonide (Budesonide) Capsule (Updated: March 2014). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a578d93-087e-42f7-a258-a49afef41dea
Budesonide capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months. /Included in US product label/
NIH; DailyMed. Current Medication Information for Budesonide (Budesonide) Capsule (Updated: March 2014). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a578d93-087e-42f7-a258-a49afef41dea
For more Therapeutic Uses (Complete) data for Budesonide (13 total), please visit the HSDB record page.
Intranasal budesonide therapy should be used with caution, if at all, in patients with clinical or asymptomatic Mycobacterium tuberculosis infections of the respiratory tract, untreated fungal or bacterial infections, or ocular herpes simplex or untreated, systemic viral infections.
American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 2810
Localized candidal infections of the nose and/or pharynx have occurred rarely during intranasal budesonide therapy. When infection occurs, appropriate local or systemic treatment of the infection may be necessary, and/or discontinuance of intranasal budesonide therapy may be required. Patients receiving the drug for several months or longer should be examined periodically for candidal infections or changes in the nasal mucosa. Nasal septum perforation and increased intraocular pressure (IOP) have been reported rarely in patients receiving budesonide nasal spray. Because corticosteroid therapy may inhibit wound healing, patients with recent nasal septum ulcers, nasal surgery, or nasal trauma should not use nasal corticosteroids until healing has occurred.
American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 2810
Patients who are taking immunosuppressant drugs have increased susceptibility to infections compared with healthy individuals, and certain infections (e.g., varicella [chickenpox], measles) can have a more serious or even fatal outcome in such patients, particularly in children. In patients who have not had these diseases, particular care should be taken to avoid exposure. It is not known how the dosage, route, and duration of administration of a corticosteroid or the contribution of the underlying disease and/or prior corticosteroid therapy affect the risk of developing a disseminated infection. If exposure to varicella (chickenpox) or measles occurs in such individuals, administration of varicella zoster immune globulin (VZIG) or pooled IM immune globulin (IG) respectively, may be initiated. If varicella (chickenpox) develops, treatment with an antiviral agent may be considered.
American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 2810
Adverse effects of budesonide occurring in 2% or more of patients receiving budesonide nasal spray and with an incidence more frequent than that of placebo include epistaxis, pharyngitis, bronchospasm, cough, and nasal irritation.
American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 2810
For more Drug Warnings (Complete) data for Budesonide (17 total), please visit the HSDB record page.
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohns disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and reducing exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression.
FDA Label
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).
Treatment of asthma
Treatment of asthma
Prevention of bronchopulmonary dysplasia
Treatment of primary IgA nephropathy
Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy
Market Place
